StockData
Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc. (IOVA) stock

IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.53−0.02 (-0.26%)

Close on Nov 17, 2026Market cap $3.41BP/E –Yield –

Iovance Biotherapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Iovance Biotherapeutics's total debt was $1.00M at Dec 31, 2024. For fiscal 2024 it was $1.00M, up 0.0% from the year before.

Annual total debt

PeriodPeriod endValueChange
FY2024Dec 31, 2024$1.00M0.0%
FY2023Dec 31, 2023$1.00M0.0%
FY2022Dec 31, 2022$1.00M0.0%
FY2021Dec 31, 2021$1.00M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024$1.00M0.0%
Q3 FY2024Sep 30, 2024$1.00M0.0%
Q2 FY2024Jun 30, 2024$1.00M0.0%
Q1 FY2024Mar 31, 2024$1.00M0.0%
Q4 FY2023Dec 31, 2023$1.00M0.0%
Q3 FY2023Sep 30, 2023$1.00M0.0%
Q2 FY2023Jun 30, 2023$1.00M0.0%
Q1 FY2023Mar 31, 2023$1.00M0.0%
Q4 FY2022Dec 31, 2022$1.00M0.0%
Q3 FY2022Sep 30, 2022$1.00M0.0%
Q2 FY2022Jun 30, 2022$1.00M0.0%
Q1 FY2022Mar 31, 2022$1.00M0.0%
Q4 FY2021Dec 31, 2021$1.00M–
Q3 FY2021Sep 30, 2021$1.00M–
Q2 FY2021Jun 30, 2021$1.00M–
Q1 FY2021Mar 31, 2021$1.00M–

More Iovance Biotherapeutics figures

See a number that looks wrong?